In this research spotlight, we feature Dr. Roddy O’Connor at the University of Pennsylvania. Dr. O’Connor works closely with CAR-T luminaries such as Carl June, and now leads his own T cell therapy research team.

As CAR-T cell therapies clear the clinic and become commercially available, advances are needed to safely and effectively improve production methods. Numerous studies have shown that the clinical efficacy of T cell therapy is tied to the maturation stage of the infused cells. Naïve and central memory T cells (see figure below) have superior expansion capability, greater in vivo persistence and reduced exhaustion leading to enhanced therapeutic performance.

Even a small increase in the activity of an infusion could save many lives. In this application note, Dr. O’Connor describes an exciting new method for preserving clinically beneficial T cell phenotypes. Download your free copy to learn his methods and findings!

T cell phenotype - CCR7 and CD45RO expression

Short on time?
Watch these two summary webinars showcasing Dr. O’Connor’s work:

T cell phenotype webinar
T cell transduction efficiency webinar
Preserving T cell naivety via a novel media supplementation strategy


Download the full application note

About the Author

Dr. Roddy O’Connor is a Senior Research Investigator at the University of Pennsylvania. His lab studies T cell metabolism and clinical applications for T cell therapy.

Get exclusive updates direct to your inbox.